| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 672.89 | 14.4% | 4.8% |
| Total Income | 686.82 | 14.0% | 5.3% |
| Expenditure | 462.77 | 8.0% | 0.9% |
| PBT | 198.39 | 13.9% | 7.2% |
| Net Profit | 150.26 | 15.6% | 9.7% |
| OPM | 30.56% | 0.09pp | 5.78pp |
| NPM | 21.88% | 0.31pp | 0.88pp |
| EPS | 12.25 | 15.6% | 9.6% |
Alivus Life Sciences Reports Strongest Performance Ever, Delivering Record Revenues of Rs 6,729 Mn and Highest Ever EBITDA Margins of 36.4%
22 Jan 2026 · 22 Jan, 2:29 pm
Summary
Alivus Life Sciences Limited, a leading developer and manufacturer of high-value, non-commoditized, Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas, reported its financial results for the quarter and nine months ended December 31, 2025. The company saw a revenue from operations of Rs. 6,729 Mn in Q3FY26, a growth of 14.4% QoQ and 4.8% YoY. The EBITDA was at Rs. 2,452 Mn, a growth of 26.5% QoQ and 22.1% YoY. The PAT for Q3FY26 stood at Rs. 1,503 Mn, a growth of 15.5% QoQ and 9.7% YoY. The company generated a strong free cash flow of Rs. 2,207 Mn leading to Cash and Cash Equivalents of Rs. 7,330 Mn as of December 31, 2025.
Key Highlights
- 1
Revenue from operations of Rs. 6,729 Mn in Q3FY26
- 2
EBITDA of Rs. 2,452 Mn in Q3FY26
- 3
EBITDA margins at record high at 36.4% in Q3FY26
- 4
PAT of Rs. 1,503 Mn in Q3FY26
- 5
PAT margins at 22.3% in Q3FY26
- 6
Generated free cash flow of Rs. 2,207 Mn during 9MFY26
- 7
Cash and Cash Equivalents of Rs. 7,330 Mn as of December 31, 2025
- 8
DMEF / CEP filings continue across major markets, taking the total cumulative filings to 595 as on December 31, 2025
- 9
HP API portfolio has 27 products in the active grid with nine products validated, seven products in advanced stages of development and 11 products under lab development stage
- 10
Solapur - Phase 1 and 1.1 construction work is in progress for 465 KL capacity
- 11
Acquired land in Taloja (Navi Mumbai) admeasuring 10,000 square meter to establish a state-of-the-art R&D centre
Management Comments
Dr. Yasir Rawjee
MD & CEO, Alivus Life Sciences Limited
This quarter showed a clear improvement in our operating performance. The CDMO business recovered as expected, delivering the turnaround we had planned for in the second half of the year. We also saw robust growth in Non-GPL business especially across our key markets, including Europe, Japan, LATAM, ROW, and India, which collectively grew by 16% YoY during 9MFY26, in-line with our guidance. For full year, we expect Non-GPL to sustain its growth momentum, reinforcing our confidence in delivering high single-digit revenue growth for FY26. Driven by the strength of our core business and increased contributions from new product launches, we remain confident of sustaining margin expansion in the current year. Our focus continues to be on building a sustainable, long-term business through high-quality offerings, innovation, and scalable operations.
Tushar Mistry
CFO, Alivus Life Sciences Limited
Our focus on disciplined and sustainable growth translated into a strong performance this quarter, with revenues reaching Rs. 6,729 million. This was accompanied by an EBITDA margin of 36.4%, the highest we have achieved so far, reflecting the strength of our diversified product portfolio and continued improvements in operational efficiency. We also remain in a strong financial position, operating as a net debt-free company. Generated free cash flow of Rs. 2,207 million during 9MFY26, and cash and cash equivalents were at Rs. 7,330 million as of 31st December 2025.
Informational and educational content only. Not investment advice.